Premium
Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against Brucella abortus and Brucella melitensis infections
Author(s) -
Abkar Morteza,
Amani Jafar,
Sahebghadam Lotfi Abbas,
Nikbakht Brujeni Gholamreza,
Alamian Saeed,
Kamali Mehdi
Publication year - 2015
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12400
Subject(s) - brucella melitensis , vaccination , brucella , immune system , immunization , biology , microbiology and biotechnology , virology , tularemia , antigen , attenuated vaccine , dna vaccination , immunology , brucellosis , virulence , gene , biochemistry
Brucellosis is a world prevalent endemic illness that is transmitted from domestic animals to humans. Brucella spp. exploits urease for survival in the harsh conditions of stomach during the gastrointestinal infection. In this study, we examined the immune response and the protection elicited by using recombinant Brucella urease ( rU rease) vaccination in BALB /c mice. The urease gene was cloned in pET 28a and the resulting recombinant protein was employed as subunit vaccine. Recombinant protein was administered subcutaneously and intraperitoneally. Dosage reduction was observed with subcutaneous ( SC ) vaccination when compared with intraperitoneal ( IP ) vaccination. rU rease induced mixed Th1–Th2 immune responses with high titers of specific IgG1 and IgG2a. In lymphocyte proliferation assay, splenocytes from IP and SC ‐vaccinated mice displayed a strong recall proliferative response with high amounts of IL ‐4, IL ‐12 and IFN ‐γ production. Vaccinated mice were challenged with virulent Brucella melitensis , B. abortus and B. suis . The SC vaccination route exhibited a higher degree of protection than IP vaccination (p value ≤ 0.05). Altogether, our results indicated that rU rease could be a useful antigen candidate for the development of subunit vaccines against brucellosis.